Efficacy of Escin Lysinate in the Prevention of Reperfusion Syndrome after Reconstructive Surgery on the Arteries of the Lower Extremities: The Change of Biochemical Markers

Objective. To optimize methods of prevention and treatment of reperfusion syndrome after reconstructive surgeries on the arteries of the lower extremities with atherosclerotic changes. Materials and methods. The study was based on the analysis of treatment in 75 patients who underwent reconstructive surgery of lower extremity arteries with atherosclerotic changes and grade IIB-IV ischemia according to Pokrovsky—Fontaine. The patients were divided into two groups comparable in age, sex, and comorbidities. Group 1 included 40 patients who received vasotropic therapy in the postoperative period, according to national guidelines for the treatment of obliterating atherosclerosis of the lower extremity arteries. Group 2 included 35 patients who received L-Lysine escinate 5.0 ml for 14 days, in addition to standard of care, after limb revascularization. Levels of lactate, myoglobin, creatinine, creatine phosphokinase (CPK), soluble fibrin monomer complexes (SFMC), D-dimer, and fibrinogen were monitored to comprehensively evaluate treatment effectiveness. Results. The study demonstrated a statistically significant improvement of key biochemical markers in the L-Lysine escinate1 group. The most pronounced changes were observed in the markers of tissue hypoxia and coagulation potential. The lactate level in the test group significantly decreased by 29.5% by Day 10 of observation (p